ATE250576T1 - Substituierte pyrrolylverbindungen zur behandlung von entzündungen - Google Patents

Substituierte pyrrolylverbindungen zur behandlung von entzündungen

Info

Publication number
ATE250576T1
ATE250576T1 AT97950891T AT97950891T ATE250576T1 AT E250576 T1 ATE250576 T1 AT E250576T1 AT 97950891 T AT97950891 T AT 97950891T AT 97950891 T AT97950891 T AT 97950891T AT E250576 T1 ATE250576 T1 AT E250576T1
Authority
AT
Austria
Prior art keywords
inflammation
treatment
substituted pyrrolyl
compounds
pyrrolyl compounds
Prior art date
Application number
AT97950891T
Other languages
English (en)
Inventor
Ish K Khanna
Richard M Weier
Yi Yu
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21866300&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE250576(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Searle & Co filed Critical Searle & Co
Application granted granted Critical
Publication of ATE250576T1 publication Critical patent/ATE250576T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/333Radicals substituted by oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/337Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT97950891T 1996-12-10 1997-12-09 Substituierte pyrrolylverbindungen zur behandlung von entzündungen ATE250576T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3268896P 1996-12-10 1996-12-10
PCT/US1997/022488 WO1998025896A1 (en) 1996-12-10 1997-12-09 Substituted pyrrolyl compounds for the treatment of inflammation

Publications (1)

Publication Number Publication Date
ATE250576T1 true ATE250576T1 (de) 2003-10-15

Family

ID=21866300

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97950891T ATE250576T1 (de) 1996-12-10 1997-12-09 Substituierte pyrrolylverbindungen zur behandlung von entzündungen

Country Status (10)

Country Link
US (1) US5935990A (de)
EP (1) EP0946507B1 (de)
AT (1) ATE250576T1 (de)
AU (1) AU5377698A (de)
CA (1) CA2273836A1 (de)
DE (1) DE69725171T2 (de)
DK (1) DK0946507T3 (de)
ES (1) ES2208964T3 (de)
PT (1) PT946507E (de)
WO (1) WO1998025896A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100485642B1 (ko) * 1996-03-18 2005-09-30 에자이 가부시키가이샤 축합고리함유카르복실산유도체
US5908858A (en) * 1996-04-05 1999-06-01 Sankyo Company, Limited 1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses
US6887893B1 (en) 1997-12-24 2005-05-03 Sankyo Company, Limited Methods and compositions for treatment and prevention of tumors, tumor-related disorders and cachexia
US6649645B1 (en) 1998-12-23 2003-11-18 Pharmacia Corporation Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
DE19953025A1 (de) 1999-11-04 2001-05-10 Merck Patent Gmbh Pyrrolderivate als Phosphodiesterase VII-Hemmer
ATE283048T1 (de) * 1999-12-08 2004-12-15 Pharmacia Corp Cyclooxygenase-2 hemmer enthaltende zusammensetzungen mit schnellem wirkungseintritt
CA2393724A1 (en) * 1999-12-23 2001-06-28 Nitromed, Inc. Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
DE19963174A1 (de) * 1999-12-27 2001-07-12 Gruenenthal Gmbh Substituierte Pyrrol-Mannichbasen
AU3653301A (en) 2000-01-28 2001-08-07 Merck & Co., Inc. Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug
AU2001255600A1 (en) * 2000-04-25 2001-11-07 Pharmacia Corporation Regioselective synthesis of 3,4-di(carbocyclyl or heterocyclyl)thiophenes
WO2002005848A2 (en) * 2000-07-13 2002-01-24 Pharmacia Corporation Use of cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
MY137736A (en) 2001-04-03 2009-03-31 Pharmacia Corp Reconstitutable parenteral composition
US6673818B2 (en) * 2001-04-20 2004-01-06 Pharmacia Corporation Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
UA80682C2 (en) * 2001-08-06 2007-10-25 Pharmacia Corp Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
AR038957A1 (es) 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
KR20050033546A (ko) 2002-04-08 2005-04-12 글락소 그룹 리미티드 (2-((2-알콕시)-페닐)-시클로펜트-1-에닐) 방향족 카르보및 헤테로시클릭산 및 유도체
US7622117B2 (en) * 2002-04-17 2009-11-24 Dynamis Therapeutics, Inc. 3-deoxyglucosone and skin
GB0212785D0 (en) * 2002-05-31 2002-07-10 Glaxo Group Ltd Compounds
CA2496225C (en) 2002-08-20 2012-08-07 Sankyo Company Limited Process for the production of .gamma.-keto acetals
JP4601274B2 (ja) * 2002-08-20 2010-12-22 第一三共株式会社 γ−ケトアセタール類の製造方法
GB0225548D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Compounds
ATE479683T1 (de) 2002-11-05 2010-09-15 Glaxo Group Ltd Antibakterielle mittel
DE10261130A1 (de) * 2002-12-20 2004-07-01 Grünenthal GmbH Arzneimittel enthaltend substituierte 2,5-Diaminomethyl-1H-pyrrole
EP1745791B1 (de) * 2003-05-07 2013-06-26 Osteologix A/S Behandlung von Knorpel/Knochen-Erkrankungen mit wasserlöslichen Strontiumsalzen
ES2394782T3 (es) * 2003-05-07 2013-02-05 Osteologix A/S Composición con estroncio y vitamina D para la profilaxis y/o tratamiento de afecciones de cartílagos y/o huesos
US20050131028A1 (en) * 2003-09-11 2005-06-16 Pharmacia Corporation Methods and compositions for the extended duration treatment of pain, inflammation and inflammation-related disorders
US7332521B2 (en) 2003-09-25 2008-02-19 Wyeth Substituted indoles
US7268159B2 (en) 2003-09-25 2007-09-11 Wyeth Substituted indoles
US7265148B2 (en) 2003-09-25 2007-09-04 Wyeth Substituted pyrrole-indoles
US7442805B2 (en) 2003-09-25 2008-10-28 Wyeth Substituted sulfonamide-indoles
GB0328024D0 (en) * 2003-12-03 2004-01-07 Glaxo Group Ltd Compounds
MX2007008227A (es) * 2005-01-05 2007-09-11 Novacea Inc Prevencion de trastornos tromboticos con compuestos de vitamina d activa o mimeticos de los mismos.
FR2887548B1 (fr) * 2005-06-27 2007-09-21 Sanofi Aventis Sa Derives de 4,5-diarylpyrrole, leur preparation et leur application en therapeutique
KR20080064956A (ko) * 2005-09-27 2008-07-10 미리어드 제네틱스, 인크. 치료학적 화합물로서의 피롤 유도체
PT1975158E (pt) * 2005-12-27 2011-09-23 Ct Nac Investigaciones Oncologicas Cnio Novos derivados de pirrole com actividade inibidora de histona desacetilase
MX2008016336A (es) * 2006-06-27 2009-01-16 Abbott Lab Derivados de tiazolina y oxazolina y sus metodos de uso.
EP2059504B1 (de) 2006-08-03 2015-09-09 Rottapharm Biotech S.r.l. 3-substituierte 1,5-diaryl-2-alkylpyrrole als hochselektive und oral wirksame cox-2-inhibitoren
CA2662870A1 (en) * 2006-09-07 2008-03-13 Myriad Genetics, Inc. Therapeutic compounds for diseases and disorders
EP2170062A4 (de) 2007-07-12 2010-12-29 Tragara Pharmaceuticals Inc Verfahren und zusammensetzungen zur behandlung von krebserkrankungen, tumoren und tumorvermittelten erkrankungen
DK2315590T3 (da) 2008-08-15 2012-11-19 N30 Pharmaceuticals Inc Pyrrolinhibitorer af S-nitrosoglutathionreduktase
WO2010019910A1 (en) 2008-08-15 2010-02-18 N30 Pharmaceuticals, Llc Novel pyrrole inhibitors of s-nitrosoglutathione reductase as therapeutic agents
DK2318007T3 (da) 2008-08-15 2013-03-25 N30 Pharmaceuticals Inc Nye pyrrol-inhibitorer af s-nitrosoglutathion-reduktase som terapeutiske midler
US10500178B2 (en) 2015-03-13 2019-12-10 The Board Of Trustees Of The Leland Stanford Junior University LTB4 inhibition to prevent and treat human lymphedema

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3168531A (en) * 1963-06-12 1965-02-02 Parke Davis & Co 1-aryl-5-(p-lower alkoxyphenyl)-pyrrole-2-propionic acid compounds
BE633582A (de) * 1963-06-13
US3427305A (en) * 1966-11-01 1969-02-11 Searle & Co 5 - ((halo/alkoxy)phenyl) - 1 - (p - sulfonamido(phenyl/benzyl)) - 2 - pyrrolepropionic acids
US3531497A (en) * 1967-02-21 1970-09-29 Upjohn Co 2,4,5 - triphenyl - (and substituted triphenyl) - 3 - acetonitriles of pyrrole
DE1938904A1 (de) * 1968-08-02 1970-02-05 Innothera Lab Sa 1-Phenylpyrrole
US5187185A (en) * 1988-12-09 1993-02-16 Rhone-Poulenc Ag Company Pesticidal 1-arylpyrroles
DE2261965A1 (de) * 1971-12-23 1973-06-28 Continental Pharma Derivate der pyrrolessigsaeure und deren salze sowie von pyrrolacetonitril, verfahren zur herstellung dieser verbindungen, diese verbindungen enthaltende pharmazeutische produkte und verwendung dieser verbindungen und produkte
US4267184A (en) * 1979-02-08 1981-05-12 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl-2-(substituted-thio)pyrroles and their corresponding sulfoxides and sulfones
US4267190A (en) * 1980-04-18 1981-05-12 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl-α,α-bis(polyfluoromethyl)-1H-pyrrole-2-methanethiols
US4335136A (en) * 1980-04-18 1982-06-15 E. I. Du Pont De Nemours And Company Anti-inflammatory 4,5-diaryl-α-(polyfluoroalkyl)-1H-pyrrole-2-methanamines
US4652582A (en) * 1985-01-09 1987-03-24 E. I. Du Pont De Nemours And Company Antiinflammatory-2-halo-4,5-diarylpyrroles
US4694018A (en) * 1985-11-29 1987-09-15 G. D. Serale & Co. Substituted 1,5-diphenyl-2-pyrrolepropionic acids and derivatives
DE3739882A1 (de) * 1987-11-25 1989-06-08 Bayer Ag Substituierte hydroxylamine
AU641905B2 (en) * 1988-12-09 1993-10-07 Rhone-Poulenc Agrochimie 1-substituted-phenyl pyrrole derivatives as insecticides and methods for their production
US5096919A (en) * 1989-01-05 1992-03-17 Ciba-Geigy Corporation Pyrrolylphenyl-substituted hydroxamic acid derivatives
DE4036706A1 (de) * 1990-11-17 1992-05-21 Hoechst Ag Verfahren zur behandlung der cardialen sowie der vasculaeren hypertrophie und hyperplasie
US5128485A (en) * 1990-12-17 1992-07-07 American Cyanamid Company Synthesis of 2-aryl-5-(trifluoromethyl)pyrroles useful as pesticidal agents and as intermediates for the preparation of said agents
EP0492093B1 (de) * 1990-12-26 1999-03-17 American Cyanamid Company Verfahren zur Herstellung von 2-Aryl-1-substituierten-5-(Trifluormethyl)-Pyrrolen als Insektizide, Akarizide und Nematizide Wirkstoffe sowie als Zwischenprodukte zur Herstellung dieser Wirkstoffe
US5144041A (en) * 1990-12-26 1992-09-01 American Cyanamid Company Process for the preparation of 2-aryl-1-substituted-5-(trifluoromethyl) pyrrole compounds useful as insecticidal, acaricidal and nematocidal agents and as intermediates for the manufacture of said agents
US5219856A (en) * 1992-04-06 1993-06-15 E. I. Du Pont De Nemours And Company Angiotensin-II receptor blocking, heterocycle substituted imidazoles
EP0764644A1 (de) * 1993-01-15 1997-03-26 G.D. Searle & Co. Verwendung von 3,4-Diarylfurane und deren Analoga enthaltende Medikamente zur Behandlung von Magen-Darm-Erkrankungen
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5908858A (en) * 1996-04-05 1999-06-01 Sankyo Company, Limited 1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses

Also Published As

Publication number Publication date
AU5377698A (en) 1998-07-03
DE69725171D1 (de) 2003-10-30
PT946507E (pt) 2004-02-27
EP0946507A1 (de) 1999-10-06
EP0946507B1 (de) 2003-09-24
DE69725171T2 (de) 2004-07-15
CA2273836A1 (en) 1998-06-18
DK0946507T3 (da) 2004-01-26
ES2208964T3 (es) 2004-06-16
WO1998025896A1 (en) 1998-06-18
US5935990A (en) 1999-08-10

Similar Documents

Publication Publication Date Title
ATE250576T1 (de) Substituierte pyrrolylverbindungen zur behandlung von entzündungen
ATE224374T1 (de) 1,2-substituierte imidazolylverbindungen zur behandlung von entzündungen
ATE233274T1 (de) Oxyiminopregnancarbolactone
MY121294A (en) Novel hexanoic acid derivatives.
NO20075065L (no) Anvendelse av isoflavonforbindelser til a behandle hjertesykdom
AU1026599A (en) Acylsulfamoyl benzoic acid amides, plant protection agents containing said acylsulfamoyl benzoic acid amides, and method for producing the same
DE122009000012I1 (de) Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzundungen.
ATE311184T1 (de) 1-benzyl-3-(substituiertes-hetaryl)-kondensiert n pyrazol-derivaten zur behandlung von erkrankungen des herz-kreislaufsystems und des zentralnervensystems
ATE242632T1 (de) Verwendung von betulinsäure-derivaten zur behandlung und vorbeugung von melanomen
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
CA2223514A1 (en) Film-forming compositions of antihyperalgesic opiates and method of treating hyperalgesic conditions therewith
ATE231837T1 (de) Hydroxamsäure- und carbonsäurederivate mit mmp und tnf hemmender wirkung
DE69634951D1 (de) Topische verwendung von betulinsäure zur behandlung bösartiger melanome
ATE350030T1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
DE69729817D1 (de) Behandlung von Aldehyd-fixierten Geweben
DE69523155D1 (de) Benzimidazolonderivate mit zentraler dopaminerger aktivität
RU94039284A (ru) Производные пиперазина, способ их получения, фармкомпозиция и ее использование
DE69530988D1 (de) Benzimidazolderivate mit dopaminerger wirkung
DE69614739D1 (de) Pflaster zur Behandlung von Pflanzen
DE60026883D1 (de) Methoden und zusammensetzungen zur behandlung von schmerzen
DE69735417D1 (de) 2,5-dihydroxybenzylsulfonderivate zur behandlung von sexuellen störungen
ATE206052T1 (de) Verwendung von sphingosin-1-phosphat, sphingosin- 1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten
ATE167804T1 (de) Verwendung von nickel und bromide ionen für die behandlung von psoriasis
DE69736180D1 (de) Behandlung von manischen erkrankungen
DE69629282D1 (de) Verwendung eines pyruvatdehydrogenaseaktivators zur behandlung der ischämie in gliedern

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0946507

Country of ref document: EP

REN Ceased due to non-payment of the annual fee